A5022422999- Vaccine Coverage and Hesitancy
- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Heparin-Induced Thrombocytopenia and Thrombosis
After the reports of severe adverse reactions to AstraZeneca ChAdOx1-S-nCoV-19 vaccine, patients who had received one dose vaccine were recommended a second Pfizer's BNT162b2 vaccine. In hemodialysis patients, we compared humoral immunogenicity and tolerability homologous vaccination with ChAdOx1-nCoV-19/ChAdOx1-nCoV-19 (ChAd/ChAd) BNT162b2/BNT162b2 (BNT/BNT) heterologous first ChAdOx1-nCoV-19 (ChAd/BNT). multicenter prospective observational study, SARS-CoV-2 spike-IgG antibody levels,...
Abstract Background In peritoneal dialysis (PD) patients, information on the immunogenicity and tolerability of SARS‐CoV‐2 vaccination is still scarce. We compared PD patients with that medical personnel. Methods a prospective observational cohort study, immunocompetent personnel were evaluated for spike‐IgG‐ Nucleocapsid‐IgG‐antibody‐levels before, 2 weeks after first, 6 second vaccine first vaccination. Results COVID‐19‐naïve ( N = 19), lower SARS‐CoV‐2‐spike‐IgG‐levels found 24) (median...